Searchable abstracts of presentations at key conferences in endocrinology

ea0031p252 | Pituitary | SFEBES2013

Craniopharyngiomas and Wnt signalling pathways

Preda Veronica , Larkin Sarah , Karavitaki Niki , Robinson Bruce , Clifton-Bligh Roderick , Grossman Ashley , Ansorge Olaf

Craniopharyngiomas are tumours which grow in the region of the sella, with adamantinomatous (ACP) and papillary (PCP) subtypes. While usually ‘benign’, They can have devastating long term sequelae, both from the mass effects of the tumour itself on the visual, pituitary or hypothalamic pathways, but also from the neurosurgical challenge to achieve tumour control with preservation of the surrounding pituitary and hypothalamic pathways. To date there is no satisfactory...

ea0081oc3.2 | Oral Communications 3: Thyroid 1 | ECE2022

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Durante Cosimo , Brose Marcia , Robinson Bruce , Sherman Steven I , Jarzab Barbara , Lin Chia-Chi , Vaisman Fernanda , Hoff Ana O , Hitre Erika , Bowles Daniel W , Sen Suvajit , Patel Purvi , Keam Bhumsuk , Capdevila Jaume

Background: At a preplanned interim analysis (median follow-up 6.2 months) of the double-blind, phase 3 COSMIC-311 trial (NCT03690388), cabozantinib significantly improved progression-free survival (PFS) vs placebo (HR 0.22, 96% CI 0.13-0.36; P<0.0001) in 187 patients with previously treated radioiodine-refractory DTC (Brose, Lancet Oncol; 2021). Patients must have received lenvatinib or sorafenib and progressed during or after 1-2 prior VEGFR inhibitors. We prese...

ea0081oc3.4 | Oral Communications 3: Thyroid 1 | ECE2022

Effect of age on efficacy and safety of cabozantinib vs placebo in patients with radioiodine refractory (RAI-R)-differentiated thyroid cancer (DTC) with progression after VEGFR-targeted therapy: subgroup analysis from Phase 3 COSMIC 311 study

Durante Cosimo , Robinson Bruce , Sherman Steven I , Krajewska Jolanta , Lin Chia-Chi , Vaisman Fernanda , Hoff Ana O , Hitre Erika , Bowles Daniel W , Hernando Jorge , Banerjee Kamalika , Levytskyy Roman M , Oliver Jennifer W , Keam Bhumsuk , Capdevila Jaume , Brose Marcia

Background: Increasing age is associated with poorer survival in DTC [Oyer SL, 2012]. In the phase 3 COSMIC-311 trial (NCT03690388), cabozantinib, an inhibitor of VEGFR2, MET, AXL and RET, significantly improved the progression-free survival (PFS) vs placebo in previously treated patients with RAI-R DTC (HR 0.22, 96% CI 0.13-0.36; P<0.0001; median follow-up 6.2 months). The impact of age on efficacy and safety was included in the prespecified subgroup analysis.</p...